Koelis Announces Designated CPT I Codes for Fusion Biopsy and Transperineal Biopsy in Prostate Cancer DiagnosisGRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid Services (CMS) has approved and finalized the creation of new dedicated Current Procedural Terminology (CPT®) Category I codes for prostate biopsies and specifically MRI fusion-guided prostate biopsy procedures.
Koelis Announces Partnership with Bot Image™ at AUA 2025New AI Technology Will Improve Prostate Biopsy Accuracy and Procedure Workflow
Koelis Announces Innovative Products at EAU 2025 enhancing MRI Fusion Biopsy Workflows and promoting Focal Therapy in Prostate CancerGRENOBLE, France, March 20, 2025 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in urology and prostate care, announced today it is attending its 17th European Urology Meeting EAU as a major sponsor and exhibitor.
KOELIS announces the first interim results of the VIOLETTE trial which evaluates the use of OBT-Fusion® technology in focal ablation of the prostate by microwave needlesGRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today passing an important milestone demonstrating the value of its Koelis Trinity 3D Ultrasound Platform as the enabling technology for prostate focal therapy: The VIOLETTE multicentric phase II trial on Targeted Microwave Ablation has finalized enrollment, published interim results in the respected BJUI Compass and will be presented at the prestigious annual French Urology meeting in Paris this week.
Koelis Announces New Compact 3D Probe to Improve Workflow and ReprocessingGRENOBLE, France and PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today the release of a new, compact 3D transducer for transperineal fusion biopsy and treatment. Koelis is now compatible with both the market leading high-level disinfection systems (Trophon® and Astra®VR).
Koelis Announces Partnership and Initial Experience with DeepHealth for AI-powered Prostate MRI Interpretation and Guidance in Fusion BiopsyGRENOBLE, France and PRINCETON, N.J., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today the partnership and successful initial experience using the DeepHealth Prostate software to streamline the prostate MRI reading process and seamless fusion of MRI with Koelis Trinity 3D Ultrasound Platform for prostate fusion biopsy and treatment.
Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy WorkflowGRENOBLE, France and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association Annual Meeting in San Antonio, TX. Koelis will be holding live and interactive demos at its booth #951 from May 2nd to May 5th to demonstrate its novel capacity integrating AI-enhanced prostate MRI features into its exclusive Trinity platform.
Koelis Announces New Products and Technology at AUA 2023GRENOBLE, France and PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association annual meeting in Chicago, IL. Koelis will be holding live and interactive demos at its booth #1652 from April 28th to May 1st to demonstrate the exclusive technology and new features of its Trinity 3D ultrasound and MRI fusion platform.
